Unknown

Dataset Information

0

Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.


ABSTRACT: BACKGROUND:Keratoconjunctivitis sicca affects 5% to 33% of the population and is often accompanied by symptoms such as burning and dryness. This pooled analysis evaluated total and central corneal fluorescein staining (CFS) in patients receiving OTX-101 0.09% or vehicle in phase 2b/3 and 3 studies and whether improvements in corneal staining correlated with improved visual acuity. METHODS:In these randomized, vehicle-controlled studies, patients received 1 drop of OTX-101 or vehicle in both eyes twice daily. Corneal staining was performed at baseline and days 28, 56, and 84. CFS was evaluated in each zone (0-to-4 scale); total corneal staining (0-to-20 scale per eye) was averaged over both eyes. Pooled safety assessments included adverse event monitoring. RESULTS:Mean baseline CFS total scores (SD) were 4.2 (2.5) and 4.3 (2.6) for the OTX-101 (n = 523) and vehicle (n = 525) groups, respectively. For total corneal staining, least squares mean changes from baseline (standard error) were -0.9 (0.08) versus -0.5 (0.08) for OTX-101 and vehicle, respectively (P = 0.0008), on day 28 and -1.4 (0.09) versus -0.9 (0.09) on day 84 (P = 0.0002). There was a significantly high correlation (P = 0.0117) between reduced central corneal staining and improved visual acuity on day 84. Treatment-related adverse events were mostly mild, with instillation site pain reported by 21.8% and 4.0% of patients receiving OTX-101 and vehicle, respectively. CONCLUSIONS:Treatment with OTX-101 led to greater improvements versus vehicle in corneal surface staining as early as 4 weeks, and further improvements were seen up to 12 weeks. OTX-101 was well tolerated in patients with keratoconjunctivitis sicca.

SUBMITTER: Malhotra R 

PROVIDER: S-EPMC6749965 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.

Malhotra Ranjan R   Devries Douglas K DK   Luchs Jodi J   Kabat Alan A   Schechter Barry A BA   Shen Lee Bridgitte B   Shettle Lee L   Smyth-Medina Robert R   Ogundele Abayomi A   Darby Charles C   Bacharach Jason J   Karpecki Paul P  

Cornea 20191001 10


<h4>Background</h4>Keratoconjunctivitis sicca affects 5% to 33% of the population and is often accompanied by symptoms such as burning and dryness. This pooled analysis evaluated total and central corneal fluorescein staining (CFS) in patients receiving OTX-101 0.09% or vehicle in phase 2b/3 and 3 studies and whether improvements in corneal staining correlated with improved visual acuity.<h4>Methods</h4>In these randomized, vehicle-controlled studies, patients received 1 drop of OTX-101 or vehic  ...[more]

Similar Datasets

| S-EPMC7811471 | biostudies-literature
| S-EPMC6710016 | biostudies-literature
| S-EPMC7284981 | biostudies-literature
| S-EPMC6384987 | biostudies-literature
| S-EPMC8326832 | biostudies-literature
2021-06-10 | GSE176510 | GEO
| S-EPMC5099351 | biostudies-literature
| S-EPMC3278229 | biostudies-literature
| S-EPMC6165102 | biostudies-other
| S-EPMC6174300 | biostudies-literature